PS 948115

Drug Profile

PS 948115

Alternative Names: PS-948115

Latest Information Update: 22 Mar 2010

Price : $50

At a glance

  • Originator Pharmacopeia
  • Developer Merck & Co
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Respiratory tract disorders

Most Recent Events

  • 25 Sep 2007 Phase-I clinical trials in Respiratory tract disorders in USA (unspecified route)
  • 11 Apr 2006 Preclinical trials in Respiratory tract disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top